Norbert Vey
Norbert Vey is an expert in Hematology at Institut Paoli-Calmettes (France). As of September 2026, ScienceLeadR ranks Norbert Vey in the top 1% of experts worldwide for Leukemia. Norbert Vey has authored 773 publications, the most recent in 2026, and is an investigator in 47 clinical trials, 3 of them ongoing. SLR score: 2,524 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1994 - 2026
Number : 773
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy. PMID 42166362 — cells, genes, hematology, leukemia, drug therapy, leukemia, myeloid, acute, leukemia, myeloid, chemotherapy | Blood | 2026 | 0 |
| [Psychosocial needs in oncology: From observation to action, a major challenge for adolescents and young adults]. PMID 41791920 — neoplasms, adolescent | Bull Cancer | 2026 | 0 |
| Intermediate-Dose Cytarabine as Postinduction AML Therapy. PMID 40552969 — cytarabine, therapeutics | NEJM Evid | 2025 | 0 |
| Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1. PMID 40474797 — cells, dasatinib, therapeutics, apoptosis, drug resistance | Br J Haematol | 2025 | 0 |
| Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. PMID 39913928 — leukemia, leukemia, myeloid, acute, leukemia, myeloid, therapeutics, hematologic diseases | Blood Adv | 2025 | 2 |
Clinical Studies 47
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher risk Myelodysplastic Syndromes NCT05782127 — myelodysplastic syndromes, safety, azacitidine, transplantation | Phase 1/Phase 2 | Active not recruiting | 2023 |
| AB8939 in Patients With Relapsed Refractory Acute Myeloid Leukemia NCT05211570 — injections, myelodysplastic syndromes, safety, gata2 deficiency, leukemia, leukemia, myeloid, acute, leukemia, myeloid, injections, intravenous, pharmacokinetics | Phase 1/Phase 2 | Recruiting | 2022 |
| COaching and Prehabilitation Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome NCT03595787 — exercise, preleukemia, cells, nutritional support, feasibility studies, myelodysplastic syndromes, microscopy, electron, scanning transmission, leukemia, stem cells, drug therapy, leukemia, myeloid, acute, leukemia, myeloid, mentoring, cell transplantation, stem cell transplantation, transplantation, chemotherapy | N/A | Active not recruiting | 2022 |
LeadR Networks
Main global connection map